No Data
Subsidiary's slow R&D progress questioned, zhejiang huahai pharmaceutical responds: 'More than 10 products have entered the clinical research stage' | Direct hit on earnings conference
①At the earnings conference, zhejiang huahai pharmaceutical's research and development pipeline progress was questioned by investors. In response, the company's secretary to the board, Zhu Yonghua, provided an overview of the pipeline under development. ②On the zhejiang huahai pharmaceutical side, due to various factors such as the growth of key original research customers, revenue from active pharmaceutical ingredients and formulations business has increased in the first three quarters of this year.
gf sec: The upstream prices of penicillin and cephalosporins are fluctuating at a high level, while the active pharmaceutical ingredient is finding a bottom and stabilizing.
According to the data from the National Bureau of Statistics, in September 2024, the month-on-month PPI value of chemical drug active pharmaceutical ingredient manufacturing was 97.10, an increase of 2.0 compared to the previous month, and an increase of 1.63 from the average of 95.47 in the first half of 2024. Since the year 2023, when the month-on-month PPI of active pharmaceutical ingredient manufacturing fell below 100 for the whole year, the recent PPI value has been in an increasing state, indicating that the overall price of active pharmaceutical ingredients is in a phase of slight bottoming and recovery.
Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Top Owners Are Individual Investors With 44% Stake, While 42% Is Held by Insiders
Pacific Securities: Q3 revenue and profit growth of the active pharmaceutical ingredient sector have accelerated significantly, bullish on the high growth trend in Q4 performance.
In Q1 2024, the gross margin of the sector was 36.38%, with a net margin of 12.78%. In Q2, the gross margin was 37.21%, with a net margin of 15.52%. In Q3, the gross margin was 38.27%, +1.88pct year-on-year, +1.06pct quarter-on-quarter, with a net margin of 14.07%, +3.98pct year-on-year, -1.45pct quarter-on-quarter, both gross margin and net margin reaching a new high compared to the same period in the past three years.
Zhejiang Huahai Pharmaceutical (600521.SH): The pharmaceutical registration certificate for Linagliptin Metformin Hydrochloride Tablets (Ⅱ) has been obtained.
On November 11th, Hua Hai Pharmaceutical (600521.SH) announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of the pharmaceutical product Linagliptin Metformin Tablets (Ⅱ). The approved product is mainly used for type 2 diabetes adult patients suitable for receiving Linagliptin and Metformin treatment, to improve the blood sugar control level of these patients.
Zhejiang Huahai Pharmaceutical Secures Clinical Trial Approval for Asthma Treatment
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its ProspectsNo Data
No Data
